The FDA on Monday granted the first full approval of Gilead’s COVID-19 drug, remdesivir, for treating the illness in children. The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age. Now, children over the age of 28 days will be able to take […]
The FDA on Monday granted the first full approval of Gilead’s COVID-19 drug, remdesivir, for treating the illness in children.
The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age.
Now, children over the age of 28 days will be able to take the drug.
The approval applies to children who are hospitalized or have mild-to-moderate disease and are at high risk of severe illness, Fox News reports.
The FDA’s decision makes the drug the first approved treatment for those under the age of 12.
